



# LKT Laboratories, Inc.

## AZD-7762 Hydrochloride

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

Product ID A9912  
CAS No. 1246094-78-9  
Chemical Name

Synonym AZD-7762 HCl

Formula  $C_{17}H_{19}FN_4O_2S \cdot HCl$   
Formula Wt. 398.88

Melting Point


Purity  $\geq 98\%$

Solubility DMSO 50 mg/mL (137.96 mM)  
Water Insoluble  
Ethanol Insoluble

Store Temp  $-20^{\circ}C$

Ship Temp Ambient

**Description** AZD-7762 is an inhibitor of checkpoint kinase (CHK) 1 that increases sensitivity to DNA-damaging compounds. AZD-7762 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for a variety of cancers. In breast cancer and ovarian cancer cells, AZD-7762 inhibits cellular proliferation. In animal models of breast cancer, AZD-7762 inhibits tumor growth and increases survival rates. This compound displays somewhat limited efficacy due to cardiac toxicity.



**Bulk quantities available upon request**

Product ID	Size
A9912	1 mg
A9912	5 mg
A9912	10 mg

**References** Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. *BMC Cancer*. 2014 Aug 7;14:570. PMID: 25104095.

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2014 Mar;73(3):539-49. PMID: 24448638.

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. *J Clin Invest*. 2012 Apr;122(4):1541-52. Erratum in: *J Clin Invest*. 2012 Jul 2;122(7):2702. PMID: 22446188.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.